Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.

about

Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.

Item

http://www.wikidata.org/entity/Q48252794

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Discontinuation of Everolimus ...... cer Patients: A Meta-Analysis.

@en

Discontinuation of Everolimus ...... cer Patients: A Meta-Analysis.

@nl

type

Item

label

Discontinuation of Everolimus ...... cer Patients: A Meta-Analysis.

@en

Discontinuation of Everolimus ...... cer Patients: A Meta-Analysis.

@nl

prefLabel

Discontinuation of Everolimus ...... cer Patients: A Meta-Analysis.

@en

Discontinuation of Everolimus ...... cer Patients: A Meta-Analysis.

@nl

P1476

Discontinuation of Everolimus ...... ncer Patients: A Meta-Analysis

@en

P2093

Shenhong Wu

http://www.w3.org/2001/XMLSchema#string

Sherise C Rogers

http://www.w3.org/2001/XMLSchema#string

P2860

Withdrawal of anticancer therapy in advanced disease: a systematic literature review

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.

Everolimus for advanced pancreatic neuroendocrine tumors.

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Processes of discontinuing chemotherapy for metastatic non-small-cell lung cancer at the end of life

P304

552-561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1080/07357907.2017.1344697

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christine Garcia

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28799817

http://www.w3.org/2001/XMLSchema#string